Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Pembrolizumab [1374853-91-4]

Pembrolizumab [1374853-91-4]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-P9902-1mg

Size : 1mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Pembrolizumab Chemische Struktur

Pembrolizumab Chemische Struktur

CAS. Nr. : 1374853-91-4

This product is a controlled substance and not for sale in your territory.

Based on 9 publication(s) in Google Scholar

Beschreibung

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

IC50 & Target

IC50: 0.6 nM (PD-1)
In Vitro

Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells[2].
? Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pembrolizumab Related Antibodies

Cell Cytotoxicity Assay[2]

Cell Line: αROR1-CAR T and A549 cells
Concentration: 10 μg/mL
Incubation Time: Adding Pembrolizumab after A549-Red-Fluc cells preconditioned in elevated pressure (+ 100 mmHg) for 7 days.
Result: Enhanced αROR1‑CAR T killing of A549 lung cancer cells under elevated pressure.

Apoptosis Analysis[2]

Cell Line: A549 cells
Concentration: 10 μg/mL
Incubation Time:
Result: Increased the apoptotic cell death in A549 cells, and improve the αROR1-CAR T-mediated cytotoxicity.
In Vivo

Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-week-old male BALB/c athymic nude mice[2]
Dosage: 5 mg/kg
Administration: Pembrolizumab (5 mg/kg; Intravenous injection; Once)
Result: Reduced tumorigenesis in αROR1-CAR T cells and co-cultured with A549 cells.
Klinische Studie
Molekulargewicht

146266.23

CAS. Nr.

1374853-91-4
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Pembrolizumab]
Versand

Shipping with dry ice.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation

Purity: 99.06%

COA (291 KB)

Handling Instructions (2659 KB)
Verweise

  • [1]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.  [Content Brief]

    [2]. Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep  [Content Brief]

    [3]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.

    [4]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.  [Content Brief]

  • [1]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.

    [2]. Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep

    [3]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.

    [4]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Pembrolizumab Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pembrolizumab1374853-91-4MK-3475 LambrolizumabMK3475MK 3475PD-1/PD-L1PD-1/Programmed death-ligand 1PD-1 inhibitorIgG4 antibody cancerimmunologyInhibitorinhibitorinhibit

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.